Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | INCAGN02385 + INCAGN02390 + Retifanlimab |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
INCAGN02385 | INCAGN 02385|INCAGN-02385 | LAG3 Antibody 17 | INCAGN02385 is a antibody that targets LAG-3, potentially resulting in increased T-cell response (AACR Annual Meeting 2018, Abstract 3919). | |
INCAGN02390 | INCAGN 02390|INCAGN-02390 | TIM-3 Antibody 8 | INCAGN02390 is an antibody that targets the immune inhibitory receptor TIM-3, potentially resulting in decreased tumor growth in combination with other immune checkpoint inhibitors (Cancer Res July 1 2018 (78) (13 Supplement) 3825). | |
Retifanlimab | MGA 012|INCMGA00012|MGA012 | Immune Checkpoint Inhibitor 141 PD-L1/PD-1 antibody 83 | Retifanlimab (INCMGA00012) is a humanized IgG4 monoclonal antibody that targets PD-1 (PDCD1) and inhibits binding of the PD-L1 (CD274) ligand, potentially resulting in enhanced anti-tumor immune response (AACR; Cancer Res 2019;79(13 Suppl):Abstract nr CT085). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04370704 | Phase Ib/II | INCAGN02385 + INCAGN02390 + Retifanlimab INCAGN02385 + INCAGN02390 | Study of Combination Therapy With INCMGA00012 (Anti-PD-1), INCAGN02385 (Anti-LAG-3), and INCAGN02390 (Anti-TIM-3) in Participants With Select Advanced Malignancies | Recruiting | USA | 0 |